Jim Cramer Says He "Believed in" Bristol-Myers' Cobenfy But "It's Not Selling Well at All"

Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer showed his disappointment in the company’s schizophrenia medicine sales, as he commented:

“Look, I, my Charitable Trust owns Bristol, looks like a mistake because I, I believed in Cobenfy, which is a, a pretty good product, but it’s not selling well at all.”

Bristol-Myers Squibb Company (NYSE:BMY) develops biopharmaceutical products for cancer, cardiovascular, autoimmune, and neurological diseases. During the September 26 episode, when a caller asked if they should add to their position in the company’s stock, Cramer replied:

“Well… I have said, and I’ve been abject about it, that I think I might be wrong in Bristol. That’s why I’ve not added to it. J&J is doing a better job than Bristol, and it’s rankling me. Let’s listen to J&J. We’re not afraid to take a loss if we have to, but we’re not giving up yet.”

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.